In our latest update, We discuss clinical and business careers with Pravin Dugel MD, President, of Iveric Bio.

We discuss with David Lally, MD   Springfield, Ma. Assistant Professor at University of Massachusetts and Tufts the use of elamipretide, a novel agent which acts at the level of the mitochondria in the treatment of geographic atrophy.

We discuss with Dr.Christoper Reimann of the Cincinnati Eye Institute the results of an early phase clinical trial in which stem cell derived retina pigment epithelial cells are injected into the sub retinal space in the maculas of eyes with geographic atrophy.

We discuss the use of suprachoroidal gene therapy for eyes with diabetic retinopathy without macular edema with Dr. Dennis Marcus, Clinical Professor of Ophthalmology, Medical College of Georgia.

We review surgical techniques for sub retinal gene therapy with Dr. Lejla Vajzovic.

Dr. Yasha Modi, Associate Professor of Ophthalmology at the NYU Langone Medical Center provides an evidence based review of management of retinal venous occlusion.

We discuss the use of a cooling probe as primary anesthesia for intravitreal injection with Ajay Kuriyan, MD, Associate Professor of Ophthalmology, Wills Eye Hospital.

We discuss blockade of complement component C1q as a novel treatment for geographic atrophy with Donald Fong, MD, Vice President Ophthalmology Clinical Development, Annexon.

We discuss clinical trials using CNTF to treat MacTel Type 2 with Dr. John Pollack, Chief Medical Officer of Neurotech Pharmaceuticals.

We asked Dr. Mohamed Genead, Chief Medical Officer, Nanoscope Therapeutics to discuss and review the latest developments in optogenetic gene therapy for retinal degenerations.